First stem cell trial halted due to costs
November 18, 2011Research and Development Geron, Stem cells
One of the world’s first stem cell trials has been put on hold due to ‘uncertain economic conditions’.Geron, the firm undertaking …
Bayer forecasts €11 billion growth in Asia
November 17, 2011Bayer, China, emerging markets
Bayer is expecting sales in Asia to grow by €11 billion over the next four years, with over half of …
Industry supports bid to revitalise antibiotic research
November 17, 2011Research and Development, Sales and Marketing EFPIA, Europe, IMI, antibiotic
The European Commission and the European pharma industry have unveiled plans to accelerate the discovery and development of new antibiotics. …
Jeremy Poland
November 17, 2011Sales and Marketing MSI Consultancy
Pharmaceutical consultancy firm The MSI Consultancy has appointed Jeremy Poland as a Graduate Analyst in its Marketing Sciences division. Jeremy …
NICE will not back Eisai’s Halaven
November 17, 2011Medical Communications, Sales and Marketing Eisai, Halaven, NICE, breast cancer
NICE has not recommended Eisai’s novel breast cancer drug Halaven due to concerns over its safety and cost.In draft guidance …
Life Healthcare makes four new appointments
November 16, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Life healthcare communications
Life Healthcare Communications has made four new appointments, adding to its client service, creative and digital teams. Vicki Marsh joins …
GSK diabetes drug fails head-to-head against Victoza
November 16, 2011Sales and Marketing GLP-1, Victoza, albiglutide, diabetes
GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like …
Multaq raises risk of death in permanent AF patients
November 16, 2011Sales and Marketing AF, Multaq, Sanofi
More bad news for Sanofi’s Multaq as new data shows the drug doubles the risk of death in people with …
Is global consistency in GCP interpretation an achievable goal?
November 16, 2011Research and Development
The potential benefits of standardisation in the conduct of an increasingly global clinical research effort are enormous. The promise of …
Quicker and slicker: new initiatives to improve clinical trial delivery
November 16, 2011Research and Development
Faster study set-up times, reduced bureaucracy and timely patient recruitment – these things are central to the success of commercial …
Infectious diseases versus clinical researchers. Who is winning?
November 16, 2011Research and Development
They were running hand in hand, and the Queen went so fast that it was all she could do to …
Full service CROs: a cost-effective option for global therapeutically focused clinical development expertise
November 16, 2011Research and Development
Skyrocketing clinical development costs are bad news for everyone, from pharmaceutical companies to patients. That’s why it’s crucial we find …
Emerging markets: comparing India and China as the future R&D hubs for the pharmaceutical industry
November 16, 2011Research and Development
The pharmaceutical industry is expanding worldwide. For the last few years, the emerging markets that offer the dynamics of growth …
Boehringer invests $65 million in early R&D centre
November 16, 2011Research and Development, Sales and Marketing Boehringer Ingelheim
Boehringer Ingelheim is investing $65 million for an early-stage research and development centre in the US. The new 72,000 sq.ft. …
Pharmacovigilance in the EU – recent and future changes
November 15, 2011Research and Development
Changes to both post-marketing and clinical trial requirements
Boehringer developing Facebook game
November 15, 2011Medical Communications Boehringer Ingelheim, Facebook
Boehringer Ingelheim is developing a new Facebook civilisation game in the hopes of helping the public understand the difficulty involved …
The roles and responsibilities of an EEA qualified person for pharmacovigilance (QPPV)
November 15, 2011Research and Development
The roles and responsibilities of an EEA Qualified Person for Pharmacovigilance are based on the current Directive 2001/83/EC and Vol …
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
UCB will double staff at Swiss bioproduction facility
November 15, 2011Manufacturing and Production UCB, manufacturing
Belgian pharmaceutical company UCB showcased its new bioproduction facility in Bulle, Switzerland, yesterday, saying that the workforce there looks set …
Joachim Christ to lead corporate controlling at Merck KGaA
November 15, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA
Joachim Christ will join Merck KGaA on 1 January next year as its new head of corporate controlling. Christ, 46, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
